Cardiogenic Shock News and Research

RSS

Cardiogenic shock is based upon an inadequate circulation of blood due to primary failure of the ventricles of the heart to function effectively.

Vaso Healthcare, GE Healthcare sign sales representative agreement

Vasomedical, Inc. today announced that its subsidiary, Vaso Diagnostics Inc. d/b/a Vaso Healthcare, has signed a sales representative agreement with GE Healthcare, the healthcare business unit of GE, for the sale of select GE Healthcare Diagnostic Imaging products. Under the Agreement, Vaso Healthcare has been appointed the exclusive representative for these products to specific market segments in the 48 contiguous states of the United States and District of Columbia.

24 May 2010

Data from Phase IV study of Bystolic tablets in Hispanic patients with hypertension presented at ASH 2010

Forest Laboratories, Inc. today presented data from a Phase IV study evaluating the effects of Bystolic (nebivolol) tablets in Hispanic patients with hypertension at the 2010 annual scientific meeting of the American Society of Hypertension.

4 May 2010

FDA accepts for review Abbott's novel diagnostic test for rapid detection of NGAL

A novel diagnostic test to rapidly detect neutrophil gelatinase-associated lipocalin (NGAL), an early biomarker that identifies patients at risk for acute kidney injury (AKI), has been accepted for review by the United States Food and Drug Administration. If approved, this would be the first test available for use in the United States for the detection of NGAL.

1 Apr 2010

Despite recommendations, nearly 14% of Medicare beneficiaries with STEMI undergo multi-vessel PCI

Nearly 14 percent of Medicare beneficiaries admitted with a primary diagnosis of ST-Segment Elevation Myocardial Infarction (STEMI) undergo multi-vessel primary percutaneous coronary intervention (PCI), despite recommendations from the American College of Cardiology and the American Heart Association to intervene on only the culprit vessel.

19 Mar 2010

Bailout stenting successful treatment for infants with constricted aortas

Cardiac interventionalists and surgeons at University Clinic in Leuven, Belgium have achieved successful stent implantation and follow-up coarctectomy in premature infants suffering from aortic coarctation. Full findings are published in the March issue of Catheterization and Cardiovascular Interventions, the official journal of The Society for Cardiovascular Angiography and Interventions.

18 Mar 2010

Aton Pharma introduces authorized generic version of Timoptic-XE

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has launched an authorized generic version of its Timoptic-XE® (timolol maleate ophthalmic gel forming solution). Timoptic-XE is a non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Aton also announced that it will continue to make available branded Timoptic-XE.

9 Mar 2010

Shock: Norepinephrine favored over dopamine

Physicians treating patients with shock should consider norepinephrine instead of dopamine as a tool for stabilizing blood pressure, according to an editorial in the March 4, 2010, issue of the New England Journal of Medicine (NEJM).

3 Mar 2010

Forest Laboratories' Bystolic tablets for treatment of stable CHF failed to receive FDA approval

Forest Laboratories, Inc. announced today that the U.S. Food and Drug Administration did not approve the additional indication for Bystolic® (nebivolol) tablets as a treatment for stable chronic heart failure (CHF) as requested in the company’s Supplemental New Drug Application (sNDA).

23 Feb 2010

FDA approves Sagent Pharmaceuticals' labetalol HCl injection for severe hypertension

Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced that it has received FDA approval of labetalol hydrochloride (HCl) injection, USP, commonly used to control severe hypertension. The product will be available in two vial sizes – 100 mg per 20 mL and 200 mg per 40 mL, multi-dose vials.

9 Feb 2010

Zevalin clinical data presented at 2009 ASH meeting

Spectrum Pharmaceuticals, Inc., a commercial stage biotechnology company with a primary focus in oncology, today announced that clinical data on ZEVALIN (ibritumomab tiuxetan) was presented at the 51st Annual Meeting of the American Society of Hematology (ASH), which was held December 5-8, 2009 at the Ernest N. Morial Convention Center in New Orleans, Louisiana.

11 Dec 2009

Aton Pharma markets preservative-free drugs for glaucoma

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has launched new education, distribution, sampling and reimbursement programs for TIMOPTIC(R) in OCUDOSE(R), the only preservative-free medication for glaucoma available in the United States. Aton acquired the U.S. marketing rights in February to the TIMOPTIC product line from Merck & Co., Inc. TIMOPTIC (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. As many as 2.25 million Americans suffer from open-angle glaucoma.

20 Aug 2009

Study offers closer look at Takotsubo cardiomyopathy

"Broken heart syndrome" is still a mystery to many in the medical community, but new data from researchers at The Miriam Hospital may shed some light on the clinical characteristics and outcomes of this relatively rare, life-threatening condition.

29 Mar 2009

Trends in heart attack explained

Explaining trends in heart attack: prevention has improved, mortality rates are down, hospitalisation remains the same

11 Mar 2009

Aton Pharma acquires Timoptic product line from Merck & Co

Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced it has acquired the U.S. marketing rights to the Timoptic product line from Merck & Co., Inc. Timoptic (timolol maleate) is a non-selective beta-adrenergic receptor blocking agent indicated for the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma.

25 Feb 2009

Senior patients benefit from selective use of early revascularization

The elderly represent a growing proportion of patients presenting with acute myocardial infarction (MI) complicated by cardiogenic shock (CS).

16 Feb 2009

Less severe first heart attacks linked to decline in coronary heart disease deaths

The severity of first heart attacks has dropped significantly in the United States - propelling a decline in coronary heart disease deaths, researchers reported in Circulation: Journal of the American Heart Association.

19 Jan 2009

Gleevec receives FDA priority review for gastrointestinal stromal tumors after surgery

Novartis has announced that Gleevec (imatinib mesylate) tablets, (known as Glivec (imatinib) outside the US, Canada and Israel), has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumors (GIST).

27 Aug 2008

OPTIMIST: The Outcome of PCI for stent-ThrombosIs MultIcentre STudy

Stent thrombosis is a recognized complication occurring in 1-2% of patients with coronary artery disease treated by percutaneous coronary intervention (PCI) with stent implantation. Its occurrence is expected to increase with the number of stent implantation procedures done worldwide. Moreover, stent thrombosis is a hot topic in the cardiology community.

3 Sep 2007

Risk stratification in acute heart failure

Hospitalization for acute heart failure is the most relevant burden for the health systems in both Europe and North America. Despite its dramatic impact on patient survival, quality of life and health costs, relatively few studies have been conducted in patients with this clinical condition in order to identify effective therapeutic strategies able to improve not only symptoms but also patient survival.

2 Sep 2007

Integrated system, rapid transfer offers lifeline for heart attack victims

Heart attack patients received lifesaving treatment quickly when hospitals and communities used an integrated, rapid transfer system to get patients to a facility equipped to perform artery-opening procedures, according to a report in Circulation: Journal of the American Heart Association.

3 Aug 2007